About
Myrtelle is developing gene therapies that target oligodendrocytes to treat myelin disorders and other neurodegenerative diseases. Its lead candidate, rAAV-Olig001-ASPA, is a proprietary AAV gene therapy for Canavan's disease and has been granted FDA Orphan Drug, Rare Pediatric Disease, and Fast Track designations.
Explore Myrtelle's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.